For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi- azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Lucky's Textbooks, Dallas, TX, Etats-Unis
Etat : New. N° de réf. du vendeur ABLIING23Apr0316110058890
Quantité disponible : Plus de 20 disponibles
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783764360320_new
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9783764360320
Quantité disponible : Plus de 20 disponibles
Vendeur : online-buch-de, Dozwil, Suisse
Hardcover Sep 01, 2000. Etat : gebraucht; sehr gut. (!) anderes Coverbild, Auflage 2000, textsauber und gepflegt. N° de réf. du vendeur 561-4-18
Quantité disponible : 1 disponible(s)
Vendeur : Romtrade Corp., STERLING HEIGHTS, MI, Etats-Unis
Etat : New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. N° de réf. du vendeur ABNR-82615
Quantité disponible : 1 disponible(s)
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. N° de réf. du vendeur ABEOCT25-246966
Quantité disponible : 1 disponible(s)
Vendeur : ALLBOOKS1, Direk, SA, Australie
Brand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address. N° de réf. du vendeur SHAK246966
Quantité disponible : 1 disponible(s)
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. Highlights anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. This work is suitable for researchers in academia and the pharmaceutical industry, and also for psychiatrists and medical students interested in this specialty. Editor(s): Briley, Mike; Nutt, David J. Series: Milestones in Drug Therapy. Num Pages: 190 pages, biography. BIC Classification: MBGR; MMGW; MMH. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 454. . 2000. Hardback. . . . . N° de réf. du vendeur V9783764360320
Quantité disponible : 15 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have ev. N° de réf. du vendeur 5279259
Quantité disponible : Plus de 20 disponibles
Vendeur : Kennys Bookstore, Olney, MD, Etats-Unis
Etat : New. Highlights anxiolytics, examining in details the strengths and weaknesses of different classes of proposed anxiolytics. This work is suitable for researchers in academia and the pharmaceutical industry, and also for psychiatrists and medical students interested in this specialty. Editor(s): Briley, Mike; Nutt, David J. Series: Milestones in Drug Therapy. Num Pages: 190 pages, biography. BIC Classification: MBGR; MMGW; MMH. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 12. Weight in Grams: 454. . 2000. Hardback. . . . . Books ship from the US and Ireland. N° de réf. du vendeur V9783764360320
Quantité disponible : 15 disponible(s)